Mark Swanson
Corporate Officer/Principal bei Gel Med Sciences, Inc.
Profil
Mark Swanson is currently the Executive Vice President at Gel Med Sciences, Inc. He previously worked as the Vice President-Transgenic Sciences at DNX Transgenic Sciences and as a Senior Scientist at Sandoz Pharmaceuticals Corp.
Dr. Swanson obtained his doctorate degree from the University of Connecticut in 1983.
Aktive Positionen von Mark Swanson
Unternehmen | Position | Beginn |
---|---|---|
Gel Med Sciences, Inc.
Gel Med Sciences, Inc. Pharmaceuticals: MajorHealth Technology Gel Med Sciences, Inc. engages in the development of animal and human healthcare products. It offers ovugel that utilizes the company's gel drug delivery system to improve the timing of artificial inseminations in pig herds. The company was founded by Joseph S Duffey in 1999 and is headquartered in Wayne, PA. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Mark Swanson
Unternehmen | Position | Ende |
---|---|---|
DNX Transgenic Sciences
DNX Transgenic Sciences Miscellaneous Commercial ServicesCommercial Services Part of Revvity, Inc., DNX Transgenic Sciences is an American company that provides contract research services and transgenic animal technologies to the biomedical research community. The company is based in NJ. DNX Transgenic Sciences was acquired by Xenogen Corp., a subsidiary of Revvity, Inc. from Nordion (Canada), Inc. on November 13, 2000 for $35 million. | Corporate Officer/Principal | - |
Sandoz Pharmaceuticals Corp. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mark Swanson
University of Connecticut | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Gel Med Sciences, Inc.
Gel Med Sciences, Inc. Pharmaceuticals: MajorHealth Technology Gel Med Sciences, Inc. engages in the development of animal and human healthcare products. It offers ovugel that utilizes the company's gel drug delivery system to improve the timing of artificial inseminations in pig herds. The company was founded by Joseph S Duffey in 1999 and is headquartered in Wayne, PA. | Health Technology |
Sandoz Pharmaceuticals Corp. | |
DNX Transgenic Sciences
DNX Transgenic Sciences Miscellaneous Commercial ServicesCommercial Services Part of Revvity, Inc., DNX Transgenic Sciences is an American company that provides contract research services and transgenic animal technologies to the biomedical research community. The company is based in NJ. DNX Transgenic Sciences was acquired by Xenogen Corp., a subsidiary of Revvity, Inc. from Nordion (Canada), Inc. on November 13, 2000 for $35 million. | Commercial Services |